EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B

Joohyun Hong iD, Jiyun Lee, Sehhoon Park, Hyun-Ae Jung, Jong-Mu Sun iD, Se-Hoon Lee iD, Jin Seok Ahn, Dong Hyun Sinn, Myung-Ju Ahn iD

Cancer · 2024-05 · 130 (9) · 1693-1701

DOI: 10.1002/cncr.35175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 02.01.2024. Verfasst von Joohyun Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi, Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Jaundice. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety of immune‐checkpoint inhibitors (ICIs) has not been thoroughly investigated in non–small cell lung cancer (NSCLC) patients with chronic hepatitis B (CHB) or occult hepatitis B infection (OBI). The authors analyzed the incidence of hepatitis B virus (HBV) reactivation, immune‐related hepatitis and jaundice in NSCLC patients in a real‐world setting.

Methods

A total of 1277 NSCLC patients treated with ICIs were analyzed. Among them, 52 patients were hepatitis B surface antigen (HBsAg) (+) (group A, CHB), 759 patients were HBsAg (–)/hepatitis B core antibody immunoglobulin G (anti‐HBc IgG) (+) (group B, OBI), and 466 patients were HBsAg (–)/anti‐HBc IgG (–) (group C). Among the 52 patients with CHB, 38 (73.1%) were receiving antiviral therapy. The primary end point was HBV reactivation, immune‐related hepatitis, and jaundice. The secondary end points included other immune‐related adverse events and efficacy.

Results

HBV reactivation was observed in two patients (0.2%) who were both in group A (CHB). Among CHB patients who were not receiving antiviral therapy, HBV reactivation was observed in 14.3% (2 of 14 patients). The incidences of immune‐related hepatitis and jaundice were comparable among the three groups. The incidence of ≥grade 3 other immune‐related adverse events and efficacy were all comparable among the three groups ( p > .05 for all comparisons).

Conclusions

In this large, real‐world cohort study, the safety and efficacy of ICIs were comparable in patients with CHB and OBI. HBV reactivation was observed in patients with CHB without antiviral therapy indicating antiviral prophylaxis should be required for them. For patients with OBI, the risk of HBV reactivation was minimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicCarcinoma, Non-Small-Cell LungLung NeoplasmsJaundiceHepatitis BHumansHepatitis B virusImmune Checkpoint InhibitorsHepatitis B Surface AntigensIncidenceCohort StudiesAntiviral AgentsImmunoglobulin GVirus ActivationDNA, Viral

Stichwörter der Autor:innen

hepatitis B virus reactivationimmune checkpoint inhibitornon–small cell lung cancer

Substanzen

Immune Checkpoint InhibitorsHepatitis B Surface AntigensAntiviral AgentsImmunoglobulin GDNA, Viral

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi, Korea.
  • Lung Cancer Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Joohyun Hong, Jong-Mu Sun, Se-Hoon Lee, Myung-Ju Ahn

Zitieren

APA

Hong, J., Lee, J., Park, S., Jung, H. A., Sun, J. M., Lee, S. H., Ahn, J. S., Sinn, D. H., & Ahn, M. J. (2024). Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B. Cancer, 130(9), 1693-1701. https://doi.org/10.1002/cncr.35175

Vancouver

Hong J, Lee J, Park S, Jung HA, Sun JM, Lee SH, et al. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B. Cancer. 2024;130(9):1693-1701. doi:10.1002/cncr.35175

BibTeX
@article{Hong2024,
  author = {Hong, Joohyun and Lee, Jiyun and Park, Sehhoon and Jung, Hyun-Ae and Sun, Jong-Mu and Lee, Se-Hoon and Ahn, Jin Seok and Sinn, Dong Hyun and Ahn, Myung-Ju},
  title = {Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {9},
  pages = {1693--1701},
  doi = {10.1002/cncr.35175}
}
Kostenlos starten →